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Abstract
Background: The potential for tolerance to develop to zafirlukast, a cysteinyl leukotriene (CysLT)
receptor antagonist (LRA) in persistent asthma, has not been specifically examined.
Objective: To look for any evidence of tolerance and potential for short-term clinical worsening
on LRA withdrawal. Outcome measures included changes in; airway hyperresponsiveness to
inhaled methacholine (PD20FEV1), daily symptoms and peak expiratory flows (PEF), sputum and
blood cell profiles, sputum CysLT and prostaglandin (PG)E2 and exhaled nitric oxide (eNO) levels.
Methods: A double blind, placebo-controlled study of zafirlukast, 20 mg twice daily over 12 weeks
in 21 asthmatics taking β2-agonists only (Group I), and 24 subjects treated with ICS (Group II).
Results: In Group I, zafirlukast significantly improved morning PEF and FEV1compared to placebo
(p < 0.01), and reduced morning waking with asthma from baseline after two weeks (p < 0.05).
Similarly in Group II, FEV1 improved compared to placebo (p < 0.05), and there were early within-
treatment group improvements in morning PEF, β2-agonist use and asthma severity scores (p <
0.05). However, most improvements with zafirlukast in Group I and to a lesser extent in Group II
deteriorated toward baseline values over 12 weeks. In both groups, one week following zafirlukast
withdrawal there were significant deteriorations in morning and evening PEFs and FEV1 compared
with placebo (p ≤ 0.05) and increased nocturnal awakenings in Group II (p < 0.05). There were no
changes in PD20FEV1, sputum CysLT concentrations or exhaled nitric oxide (eNO) levels.
However, blood neutrophils significantly increased in both groups following zafirlukast withdrawal
compared to placebo (p = 0.007).
Conclusion: Tolerance appears to develop to zafirlukast and there is rebound clinical
deterioration on drug withdrawal, accompanied by a blood neutrophilia.
Introduction
The cysteinyl leukotrienes (CysLTs), LTC4, LTD4, and
LTE4, contribute to airway inflammation and bronchoc-
onstriction in asthma [1-3]. Cysteinyl leukotriene receptor
antagonists (LRAs) and synthesis inhibitors are widely
used as anti-asthma therapies and they have been con-
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tion and clinical status as well as reduce exacerbation rate
and airway inflammation. However, in clinical practice,
therapeutic response is difficult to predict and quite varia-
ble. Head to head studies have confirmed that inhaled
corticosteroids (ICS) and ICS/long-acting β2-agonist com-
binations are superior to the LRAs in achieving clinical
control and the place of LRAs in asthma management
guidelines remains uncertain [4-7]. Studies of LRAs have
confirmed their safety and this is one of the attractions
compared to ICS therapy, but no studies have specifically
looked for evidence of tolerance or rebound deterioration
on drug withdrawal.
Zafirlukast (Accolate®, Astra Zeneca) is a highly selective
LTD4 antagonist [8]. The primary objective of this study
was to determine whether the clinical benefits of zafirlu-
kast 20 mg twice daily (b.d) would be sustained over 12
weeks treatment and whether there was any potential for
short-term deterioration in asthma control following drug
withdrawal. We were secondarily interested in whether
clinical benefits were related to any potential anti-inflam-
matory effects of zafirlukast and whether these would sim-
ilarly deteriorate on drug cessation. Treatment was
assessed in two distinct groups of subjects with persistent
asthma: in symptomatic subjects maintained on β2-ago-
nists alone and in subjects with persistent asthma symp-
toms despite moderate doses of ICS. Both of these
asthmatic groups are ones in which clinicians may con-
sider the use of a LRA.
Methods
Subjects (Table 1)
Non-smoking adult subjects with a history of at least one
year of persistent asthma symptoms treated with either β2-
agonists alone (Group I) or β2-agonists plus moderate/
high dose of ICS (≥ 800 μg Budesonide or equivalent
daily), for a minimum period of four weeks (Group II)
were eligible for participation. Exclusion criteria included:
history of an asthma exacerbation, upper respiratory tract
infection or alteration in asthma medication within six
weeks, or use of oral corticosteroids within three months
of screening. Patients were also excluded if they had
received a long-acting β2-agonist (LABA), anticholinergic,
cromone or theophylline during the six weeks prior to the
screening visit. Volunteers were recruited through adver-
tisement. The study was approved by the Alfred Hospital's
Research Ethics Committee and written informed consent
was obtained from each person.
Study design (Figure 1)
This was a 13 week, single centre, randomised, double
blind, placebo-controlled study. A pre-study visit to con-
firm selection criteria was followed by a second visit for
randomisation after a one-week screening period. Figure 1
gives details of investigations and procedures performed
at each study visit. To be eligible, subjects had to demon-
strate significant bronchodilator reversibility (BDR) i.e. ≥
15% increase in FEV1 after 400 μg of salbutamol or signif-
icant diurnal PEF variability (≥ 15%) during the run-in
period. All subjects had to have a baseline FEV1 of ≥ 60%
predicted after withholding inhaled β2-agonists for six
hours. Before randomisation, subjects needed a mini-
mum cumulative symptom score (asthma severity score)
of ≥ 10 (maximum 21), over the last seven days of the
screening period using a daily three point scale; 0 = no
symptoms, 1 = mild symptoms not interfering with activ-
ities, 2 = moderate symptoms interfering with some activ-
ities, 3 = severe symptoms interfering with most activities.
Eligible subjects were randomised to either zafirlukast 20
mg b.d or placebo b.d on a two to one basis using a com-
puter-generated random number scheme by the hospital
research pharmacist, who then dispensed zafirlukast and
placebo as identical tablets in identical blister packs.
Subjects withheld inhaled β2-agonists for six hours and
study medication on the morning of each visit except for
visit five (see below). Spirometry was performed at every
visit using a calibrated electronic spirometer (MedGraph-
ics, Minneapolis, Minenesota US) and the best of three
technically acceptable FEV1 measurements was recorded.
Clinical outcome measures
Daily asthma symptom scores, relief medication use and
nocturnal awakenings were recorded on a diary card.
Table 1: Patient demographics at baseline
β2-agonists + Placebo 
(N = 7)
β2-agonists + Zafirlukast 
(N = 14)
ICS-treated + Placebo 
(N = 8)
ICS-treated + Zafirlukast 
(N = 16)
Sex, male/female 3/4 8/6 2/6 9/7
Age, years 29 (21–55) 42 (21–69) 45 (30–65) 37 (19–65)
Ex-smoker 2 4 5 6
FEV1, L 2.7 (2.3–3.7) 2.1 (1.4–4.2) 2.8 (2.0–3.8) 2.7 (1.4–4.1)
Baseline FEV1, % predicted 80 (65–102) 85 (69–107) 76 (60–95) 77 (56–98)
Inhaled corticosteroid, μg/day NA NA 1600 (1000–2400) 1600 (1000–2400)
PD20 methacholine, μg * 0.008 (0.001–0.04) 0.04 (0.005–1.3) 0.03 (0.004–0.2) 0.02 (0.001–0.6)
Data are given as median and (range) except * geometric mean and (range). NA not applicablePage 2 of 11
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recorded each day before use of inhaled β2-agonist or
administration of study medication. For analysis, diary
card entries were assessed at three weeks, six weeks, at the
end of active treatment (week 13) and following study
drug withdrawal (week 14).
Airway hyperresponsiveness and indices of inflammation
Methacholine challenge
AHR to inhaled methacholine challenge was performed
according to a standardised protocol. [9] Results were
expressed as PD20FEV1, the cumulative dose of metha-
choline estimated to provoke a 20% decrement in FEV1
determined by linear interpolation between the last two
points on the dose-response curve. At visit 5, the broncho-
protective effect of zafirlukast vs placebo was determined
by performing methacholine challenge two hours after
observed administration of the morning dose of study
drug.
Sputum induction and processing
Subjects were pre-medicated with inhaled salbutamol 400
μg and after 15 minutes they inhaled hypertonic saline
(4.5%, DeVilbiss Ultrasonic Nebuliser, Jackson, Tennes-
see) for five minutes before being asked to expectorate
sputum. Before coughing, saliva was discarded to mini-
mise buccal contamination. This procedure was repeated
to a maximum of six nebulisations. FEV1 was measured if
the patient felt uncomfortable and sputum induction was
terminated when the subject had expectorated ≥ 2.5 mLs
of sputum with visible airway "plugs". Following sputum
induction, FEV1 was measured and salbutamol adminis-
tered if FEV1 was ≤ 80% of the pre-induction value.
Whole sputum sample processing and cell counting was
performed according to the methods of Fahy [10]. Briefly,
a volume of dithiothreitol 0.1% (Sputalysin; Calbiochem
Ltd. CA, USA) equivalent to four times the weight of spu-
tum was added. The sample was placed in a water bath at
38°C for 30 minutes and mixed at intervals to ensure ade-
quate homogenisation. The sample was then centrifuged
(Shandon II cytocentrifuge) at 1500 rpm for 10 minutes
and cell-free supernatant decanted and stored at -80°C
(see later). The cell pellet was resuspended with phos-
phate buffered saline to the original sputum volume. A
total cell count was performed in a Neubauer hemocy-
tometer and the resuspended sample spun in a cytocentri-
fuge (Shandon cytospin III, Runcorn, UK; 82 g) for 10
minutes. Cytospots were stained with Diff-Quik and two
slides per sputum sample were analysed by an observer
blinded to subject. At least 200 non-squamous cells were
counted on each slide and the results averaged. A sputum
sample was considered adequate if the percentage of squa-
mous cell contamination was less than 80% [11].
Total cysteinyl leukotriene and prostaglandin E2 assays
CysLT and PGE2 were extracted from induced sputum
supernatants by immunoaffinity purification using affin-
ity sorbents (mouse monoclonal cysLT or PGE2 antibody
covalently bound to Sepharose 4B, Cayman Chemical,
Ann Arbor, MI, USA). After thawing, 0.2 ml of sputum
supernatant was incubated with 20 μl of cysLT affinity
sorbent or 50 μl of PGE2 affinity sorbent with gentle mix-
ing for 1 h at room temperature. After centrifugation
(10,000 rpm, 4 min), the supernatant was discarded and
the sorbent pellet was washed with 1 ml of PBS. CysLT or
PGE2 were then eluted from the sorbents with 1 ml of
methanol or 95% ethanol, respectively. The methanol or
Study DesignFigure 1
Study Design. BDR bronchodilator reversibility, PbE peripheral blood eosinophils, SpE sputum eosinophils, eNO exhaled nitric 
oxide levels.Page 3 of 11
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uum and then resuspended in enzyme immunoassay
buffer. Total CysLT (LTC4/LTD4/LTE4) and PGE2 concen-
trations were determined with specific enzyme immu-
noassay kits according to the manufacturer's instructions
(Cayman Chemical). Using this methodology, processing
with DTT has been shown to have no effect on detectable
levels of sputum CysLT or PGE2 [12]. Recoveries of cysLT
and PGE2 through the extraction and enzyme immu-
noassay were assessed by spiking sputum supernatants
with known amounts of LTD4 and PGE2, with the
unspiked samples being assessed in parallel for endog-
enous concentrations of cysLT and PGE2. The mean recov-
ery of LTD4 was 65.5% ± 10.9% (SEM, n = 8) and the
mean recovery of PGE2 was 115.8 ± 8.8% (SEM, n = 8).
Exhaled breath nitric oxide determination
NO measurements were obtained using the method
described by Silkoff with patients inhaling NO-free gas
(Medical Air, Air Liquide Australia, Melbourne) and
exhaling against a fixed resistance to ensure closure of the
soft palate [13].
Exhaled NO (eNO) was measured using a fast response,
high sensitivity chemiluminescence analyser (Sievers
NOA 270 B, Boulder, Colorado, USA) with a lower detec-
tion limit for NO of 0.3 parts per billion (ppb).
The mean concentration of the plateau phase of the single
breath test was recorded from 3 technically acceptable
measurements.
Statistical Analysis
Independent professional statistical advice was obtained
for the analysis. Analyses were performed according to the
distribution of the data with or without log transforma-
tion. Clinical data are expressed as least square means
with standard errors of the means (SEM). Sputum and
blood results are expressed as median and range. Changes
in diary card and lung function parameters with treatment
were compared using a repeat measures analysis of co-var-
iance (ANCOVA) with the mean of the variables for the
last seven days of the diary card during run-in as a covari-
ate. Changes in diary card entries were assessed based on
the mean recordings for the last 14 days of the study treat-
ment periods between baseline and five weeks and
between six weeks and 10 weeks (inclusive). The mean
diary card recordings for the week prior (week 11) to study
drug withdrawal at week 12 were then compared to base-
line and the mean recordings for the one-week post-with-
drawal. Within-treatment group changes from baseline
for normally distributed data were assessed using paired t-
tests. If there appeared to be a deviation from normality,
statistical analysis was repeated using Wilcoxon's sign
rank test to confirm the ANCOVA. Sputum and blood
results were analysed according to the non-normal distri-
bution of the data: Mann-Whitney U test was used to test
differences between treatments and Wilcoxon was used to
determine within-treatment group effects. Analyses were
based on an intention to treat (ITT) principle wherever
data were available, in order to allow several minor proto-
col violators to be included in-spite of the danger of posi-
tive signals being diluted. AHR data are presented as
geometric means and ranges for PD20FEV1. Changes from
baseline for PD20FEV1 values after acute dosing and follow-
ing washout are expressed as a doubling concentration
dose of methacholine using the following formula:
[Log10 PD20FEV1 (treatment) - Log10 PD20FEV1(baseline)]/
log102
The study was designed to detect a doubling dose differ-
ence of 1.0 in PD20FEV1 between weeks 0 and 12 between
the treatment arms in each asthmatic subpopulation stud-
ied (12 patients on zafirlukast and six on placebo) with
80% power. Correlations between categorical variables
were analysed using Spearman's rank test. Statistical anal-
yses were undertaken in SPSS with a two-tailed p ≤ 0.05
being considered statistically significant.
Results
Adverse events and withdrawals
Twenty-one subjects using β2-agonists alone (median age
41 years, range 21–69 years, 10 female; Group I), and 24
asthmatic subjects maintained on ICS (median age 42
years, range 19–65 years, 14 female; Group II), met the
entry criteria for the study.
In Group I, of 14 subjects randomised to zafirlukast, one
withdrew consent shortly after randomisation for per-
sonal logistic reasons and another subject withdrew for
similar reasons after four weeks treatment. One subject
developed an upper respiratory tract infection and asthma
worsening following cessation of zafirluklast and was
unable to undergo repeat determination of eNO levels at
visit six. One additional subject did not complete their
diary card following zafirlukast withdrawal, because this
occurred over the Christmas period. Two subjects com-
pleted the study but did not undergo methacholine chal-
lenge at visit five: one subject was unable to withhold
rescue medication for six hours prior to testing, and
FEV1deteriorated to < 60% predicted pre-test in another
subject, thus precluding methacholine challenge. Of the
seven subjects in Group I randomised to placebo, one
withdrew consent shortly after randomisation and one
subject completed the study but did not undergo metha-
choline challenge at visit five because of worsening lung
function. Twelve subjects in Group I randomised to
zafirlukast and five subjects in the placebo arm therefore
completed the entire active treatment phase.Page 4 of 11
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to zafirlukast did not complete the treatment phase of the
study; one subject because of worsening rheumatoid
arthritis, one was found to have been inappropriately ran-
domised because of neutropenia at screening and one
subject developed angina necessitating cardiology referral.
Two of these subjects completed the first four weeks of the
study and their data were therefore entered into the pro-
spective analyses. Following cessation of zafirlukast in
Group II, two subjects developed clinical asthma worsen-
ing and one of these suffered a frank asthma exacerbation
requiring oral corticosteroids. Outcome analysis in this
sub-population was therefore based on the 15 subjects
randomised to zafirlukast and eight randomised to pla-
cebo.
Adherence was assessed at each study visit by tablet count-
ing and was found to be greater than 90% in all volunteers
for the duration of the study.
Clinical outcomes
In both groups overall, there was a pattern of improve-
ment over the first two weeks with zafirlukast, but these
changes then deteriorated back to baseline, or below base-
line, by 12 weeks, with further deterioration or even frank
exacerbation in one individual, in the withdrawal period.
These changes were most marked in Group I, whereas in
Group II there was some confounding by more general
trends toward improvement in both active and placebo
arms, probably related to "trial-induced" improvement in
adherence to ICS therapy.
In Group I, initial improvement compared to placebo was
most marked for laboratory-measured FEV1 and home
recorded morning PEF (p < 0.01), with borderline levels
of significance for early improvements in total mornings
per week awakening with asthma (p = 0.03), total awak-
enings with asthma (p = 0.09) and β2-agonist use (p =
0.06) for within-treatment group comparisons. Following
withdrawal of zafirlukast there were significant deteriora-
tions in FEV1 and evening PEF compared to placebo (p =
0.05, p = 0.03, respectively). Additionally, within-treat-
ment group comparisons also revealed a significant dete-
rioration in morning PEF (p < 0.001) for zafirlukast.
In Group II, only FEV1 improved significantly (p = 0.04)
after 2 weeks treatment with zafirlukast compared to pla-
cebo. Within-treatment group comparisons revealed sig-
nificant improvements in morning PEF (p = 0.01), β2-
agonist use (p = 0.02) and asthma severity scores (p =
0.02), and a trend toward improvements in evening PEF
(p = 0.08). There were subsequent deteriorations in the
group as a whole in morning and evening PEFs and morn-
ings waking with asthma after six weeks of treatment com-
pared to baseline. Following withdrawal of zafirlukast,
FEV1 deteriorated significantly compared to placebo, (p =
0.04), and there were within-treatment group rebound
deteriorations in evening PEF (p < 0.005) and nocturnal
awakenings (p = 0.04).
Overall, with both groups combined, these changes in
morning and evening PEF and FEV1 reached statistical sig-
nificance compared to placebo (p < 0.05). Thus, of partic-
ular note was the quite definite deterioration in both
asthmatic groups on cessation of zafirlukast in a range of
indices. These general trends are illustrated by the changes
that occurred in morning PEF in Group I (figure 2), but
these are reasonably typical of physiological and clinical
changes across the board (tables 2 &3). All together, there
were five clinical exacerbations on stopping active medi-
cation, and none on stopping placebo. One of the subjects
in Group II required a short-course of rescue oral CS fol-
lowing zafirlukast withdrawal.
In both groups, there was no relationship whatsoever
between deterioration on zafirlukast withdrawal and the
initial improvements observed when treatment was insti-
tuted i.e. those who deteriorated the most were not those
who had derived the greatest initial benefit with zafirlu-
kast.
Methacholine challenge
AHR at baseline was similar in both asthmatic groups
(Table 1). We were unable to assess treatment differences
in Group I because of the small numbers who underwent
repeated testing at the end of active treatment and follow-
ing withdrawal. However, comparison of Group I baseline
results to those after acute active dosing at visit 5 revealed
a trend for geometric mean PD20FEV1to rise from 0.038 μg
to 0.057 μg, representing a 0.6 doubling-dose (DD)
improvement (p = 0.07).
In Group II, the effect of zafirlukast was not significantly
different to placebo, with PD20 methacholine improving
in both treatment arms. Within-treatment group analysis
demonstrated a small but significant rise in geometric
mean PD20FEV1 from 0.025 μg at baseline to 0.042 μg (DD
of 1.3; p < 0.05), after acute active dosing at visit 5, but
this was not different to placebo given at the same time.
There was no significant deterioration in PD20FEV1 in
either asthmatic group following zafirlukast withdrawal.
Indeed, in Group II, comparing end of washout with pre-
study test results revealed a persisting improvement in
PD20FEV1 of 1.2 DD, which was significant (p < 0.05), but
changes with placebo were similar though smaller. These
changes probably reflect improved adherence with ICS
therapy.Page 5 of 11
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Table 2: Effects of zafirlukast in asthmatic subjects maintained on β2-agonists alone
β2-agonists alone + Placebo Change from baseline β2-agonists alone + Zafirlukast Change from baseline
Baseline 
(N = 7)
Weeks 0–5 
(N = 6)
Weeks 6–10 
(N = 5)
Week 11–12 
(N = 5)
*W/D 
(N = 5)
Baseline 
(N = 14)
Weeks 0–5 
(N = 13)
Weeks 6–10 
(N = 12)
Week 11–12 
(N = 12)
*W/D 
(N = 11)
Daily PEFR a.m., L/min 375 (± 36.7) -17.3 (± 8.6) -12.2 (± 10.3) +0.8 (± 7.5) -1.2 (± 4.3) 408 (± 30.9) +14.9 (± 7.9) +1.6 (± 8.5) -3.2 (± 11.5) -30.7 (± 10.9)
Daily PEFR p.m., L/min 374 (± 35.0) +4.9 (± 6.6) +14.2 (± 10.7) +21.2 (± 11.7) -9.4 (± 8.9) 430 (± 27.4) +4.2 (± 4.4) -0.08 (± 5.7) -5.8 (± 7.5) -12.7 (± 8.2)
FEV1, mL 2.82 (± 0.33) -170 (± 80) +20.0 (± 10) -258 (± 213) +7.2 (± 128) 2.90 (± 0.16) +110 (± 60) -12.5 (± 6.9) +14.2 (± 72) -214 (± 69.8)
β2-agonist use per day 4.6 (± 0.9) -0.7 (± 0.3) -1.3 (± 0.4) -0.6 (± 0.5) +0.2 (± 0.5) 3.7 (± 0.5) -0.7 (± 0.4) -0.4 (± 0.5) +0.2 (± 0.5) +0.6 (± 0.3)
Severity score 1.9 (± 0.05) -0.2 (± 0.1) -0.3 (± 0.1) -0.2 (± 0.2) -0.04 (± 0.2) 1.8 (± 0.08) -0.2 (± 0.1) -0.2 (± 0.1) -0.2 (± 0.2) +0.3 (± 0.2)
**Total mornings 4.1 (± 1.0) -0.07 (± 0.5) -0.2 (± 0.3) -0.8 (± 0.4) -0.2 (± 0.5) 3.5 (± 0.7) -1.1 (± 0.5) -0.8 (± 0.6) -0.3 (± 0.7) +0.1 (± 0.5)
**Total awakenings 3.7 (± 1.3) -1.1 (± 0.7) -0.3 (± 1.7) +0.7 (± 2.4) -0.2 (± 0.7) 1.4 (± 0.5) -0.8 (± 0.4) -0.9 (± 0.5) +0.2 (± 0.7) +0.9 (± 0.8)
Table 3: Effects of zafirlukast in subjects maintained on ics
ICS-treated + Placebo Change from baseline ICS-treated + Zafirlukast Change from baseline
Baseline 
(N = 8)
Weeks 0–5 
(N = 8)
Weeks 6–10 
(N = 8)
Week 11–12 
(N = 8)
*W/D 
(N = 8)
Baseline 
(N = 15)
Weeks 0–5 
(N = 15)
Weeks 6–10 
(N = 13)
Week 11–12 
(N = 13)
*W/D 
(N = 11)
PEFR a.m., L/min 353 (± 32.3) +13.9 (± 6.1) +21.1 (± 9.6) +17.5 (± 12.2) +10.4 (± 6.6) 389 (± 21.2) +15.7 (± 5.0) +16.7 (± 6.1) +2.7 (± 15.2) -7.4 (± 6.3)
PEFR p.m., L/min 373 (± 32.8) +9.4 (± 10.0) +6.4 (± 15.0) +17.7 (± 12.1) +5.3 (± 6.2) 404 (± 20.0) +10.5 (± 4.9) +10.9 (± 5.8) -0.6 (± 15.0) -23.1 (± 6.6)
FEV1, mL 2,567 (± 225) -134 (± 67.7) -130 (± 47.2) -23.8 (± 93.6) +78.8 (± 59.6) 2,540 (± 179) +105 (± 72.5) -39.2 (± 74.7) +144 (± 106) -94.5 (± 48.0)
β2-agonist use per day 3.9 (± 0.6) -0.8 (± 0.47) -1.2 (± 0.68) -0.3 (± 1.0) -0.4 (± 0.4) 3.7 (± 0.5) -0.8 (± 0.25) -0.9 (± 0.32) -1.1 (± 0.4) +0.6 (± 0.47)
Severity score 2.0 (± 0.02) -0.3 (± 0.1) -0.3 (± 0.1) -0.03 (± 0.04) -0.1 (± 0.1) 1.8 (± 0.7) -0.3 (± 0.1) -0.3 (± 0.1) -0.4 (± 0.2) +0.1 (± 0.2)
**Total mornings 5.7 (± 0.8) -1.8 (± 0.8) -3.2 (± 0.9) -2.3 (± 1.4) -0.8 (± 2.2) 3.2 (± 0.6) -0.7 (± 0.4) -1.1 (± 0.7) -0.6 (± 0.5) +0.4 (± 0.3)
**Total awakenings 1.5 (± 0.9) -0.8 (± 0.7) -0.8 (± 0.5) -1.1 (± 0.7) +0.4 (± 1.1) 1.8 (± 0.7) -0.6 (± 0.5) -0.9 (± 0.6) -1.6 (± 0.7) +1.4 (± 1.0)
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(Tables 4 &5)
Sputum eosinophils and PbE were closely related to each
other in both asthmatic groups at baseline (r(s) = 0.8 &
r(s) = 0.8, p < 0.001 respectively). Satisfactory baseline
sputum samples were obtained from 31 subjects (Group
I; n = 15, Group II, n = 16), and 24 subjects provided ade-
quate paired samples (Group I; n = 13, Group II, n = 11).
For sputum analysis we have therefore combined the
groups (zafirlukast; n = 13). Paired blood samples were
available in 37 subjects overall (zafirlukast; n = 23). There
were no significant changes in either SpE or PbE numbers
with 12 weeks treatment with zafirlukast, and there was
also no increase in PbE on withdrawal of zafirlukast.
Zafirlukast treatment had no effect on sputum or periph-
eral blood neutrophils, but following withdrawal there
was a significant rise in median number of circulating
neutrophils in both groups overall compared to placebo
(3.2 × 109/L, range 1.6–4.2 × 109/L to 3.5 × 109/L, range
1.7–5.1 × 109/L versus 4.1 × 109/L, range 2.8–5.4 × 109/L
to 3.4 × 109/L, range 2.2–5.5 × 109/L respectively, p =
0.007). This was most marked in the β2-agonist only
group when post-withdrawal neutrophils rose uniformly
compared to end of active treatment numbers; 3.0 × 109/
Effects of zafirlukast on morning PEF in asthmatic subjects maintained on β2-agonists aloneFigure 2
Effects of zafirlukast on morning PEF in asthmatic subjects maintained on β2-agonists alone. Solid line represents zafirlukast and 
dashed line, placebo. Only data from subjects completing the entire study are illustrated. *p = 0.01 compared to placebo, **p < 
0.001 compared to before withdrawal.
Table 4: Sputum and peripheral blood cellular profiles at baseline
β2-agonist alone ICS-treated Significance
*TCC × 103/ml 41.5 (11.1–235.3) 30.0 (0.5–293.8) NS
Sputum eosinophils, % 4.6 (0.8–20.4) 6.0 (0.2–39.2) NS
Cys-LT pg/ml 266.4 (1.0–1343.6) 297.6 (60.3–763.1) NS
PGE2pg/ml 966 (371.6–1950.5) 1358,5 (149.1–6155.3) NS
PB eosinophils, × 109 4.3 (1.1–12.7) 3.3 (1.2–9.8) NS
PB neutrophils, × 109 3.2 (2.0–6.2) 3.65 (1.1–6.2) NS
eNO (ppb) 31 (9–77) 15 (8–32) p < 0.001Page 7 of 11
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109/L, p = 0.005). There was no statistical relationship
between the observed changes in blood neutrophils and
clinical deteriorations on zafirlukast withdrawal.
Sputum CysLT and PGE2 levels (Table 5)
Sufficient paired sputum supernatants for analysis were
available in 20 subjects. There was a trend for increased
CysLT levels in Group I at baseline (p = 0.08), but no dif-
ference in PGE2 concentrations. Paired sputum superna-
tants were available for analysis in nine subjects who
received zafirlukast (Group II; n = 3) and 11 subjects who
received placebo (Group II; n = 7). Overall, with both
groups combined there was no suggestion of a treatment
effect on CysLT levels. Similarly, there was no suggestion
that zafirlukast affected sputum PGE2 levels or the CysLT/
PGE2 ratio.
CysLT and PGE2 levels at baseline and at the end of treat-
ment were not related to any of the observed clinical out-
comes in those subjects who received zafirlukast.
Exhaled nitric oxide levels
As expected, eNO levels were significantly higher in
Group I asthmatics (median 31 ppb, range 9–77 ppb)
compared to Group II (15 ppb, 8–32 ppb) at baseline (p
< 0.0001).
There were no changes in eNO levels in either asthmatic
group following treatment with zafirlukast and no rise in
eNO following treatment withdrawal.
Discussion
Our findings demonstrate that early clinical improve-
ments in asthmatic subjects treated with zafirlukast grad-
ually wane to baseline values over a 12 week treatment
period. Asthma control then significantly deteriorated
overall when zafirlukast was withdrawn, i.e. to worse than
baseline in many patients, especially in those not treated
with an ICS. The changes with treatment and on with-
drawal were less obvious in asthmatic subjects main-
tained on moderate doses of ICS (Group II), but the
parallel improvement in the placebo group in this sub-
population suggest our findings were probably con-
founded by improved adherence to ICS therapy as tends
to occur during research studies. There was no evidence of
an anti-inflammatory effect for zafirlukast, but drug with-
drawal was accompanied by a significant increase in circu-
lating neutrophils in both asthmatic groups. The changes
with zafirlukast in both asthmatic populations were
remarkably consistent and strongly suggest the develop-
ment of tolerance and rebound deterioration on treat-
ment withdrawal.
The leukotriene receptor antagonists (LRAs) have been
attributed with potential disease modifying effects,
although most of the evidence for an anti-inflammatory
effect comes from studies of montelukast. [14-16] No pre-
vious direct evidence of tolerance to the LRAs has been
presented in persistent asthma, although studies of exer-
cise-induced asthma do suggest that tolerance can
develop, but what may be most important is the dose and
type of LRA used. [17] Ours is the first clinical study to
prospectively demonstrate this possibility in persistent
asthma and the challenge is to explain these findings in
the light of large studies that have failed to find such an
effect. [17,18]
The majority of studies of zafirlukast have been under-
taken over short periods of six weeks or less, which may
not have allowed sufficient time for tolerance or tachyph-
ylaxis to develop or to be recognised. In our study, definite
loss of clinical benefit generally occurred from the sixth
week of treatment onward in both asthmatic groups, sug-
gesting shorter treatment courses may not allow enough
time for tolerance to occur. Although a handful of studies
have demonstrated zafirlukast 20 mg bid over 12 weeks
and longer to be significantly superior to placebo, the
majority of clinical benefit has usually occurred within
four weeks with little change thereafter. [19-21] Only
larger than conventional doses of zafirlukast have shown
improvements consistent with an anti-inflammatory
effect, but whether tolerance develops to such aggressive
dosing regimes remains unknown. [5]
The significant physiological deteriorations to below
baseline values, especially in Group I, on zafirlukast with-
drawal are inconsistent with simple removal of a bron-
Table 5: Effects of zafirlukast on sputum inflammatory indices in paired samples
Zafirlukast (n = 9) Placebo (n = 11)
Baseline 12 weeks Baseline 12 weeks
*TCC × 103/ml 38.8 (0.6–293.8) 22.8 (0.3–93.8) 41.0 (0.5–176) 41.5 (3.8–109.3)
Sputum eosinophils, % 5.8 (0.8–39.2) 4.0 (0.4–54.6) 5.3 (0.2–14.7) 1.7 (0–39.5)
CysLT pg/ml 331 (182–648) 567 (151–1029) 192 (15–763) 412 (49–1332)
PGE2 pg/ml 942 (572–1951) 1276 (836–2513) 1245 (479–6155) 959.2 (329–3756)
*Data are expressed as median and (range).Page 8 of 11
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subjects had already deteriorated back to baseline values
by the end of active treatment. There was a clear "over-
shoot" to worse than study entry values in essentially all
lung function and clinical parameters. There was also no
relationship between initial improvements and subse-
quent deteriorations on zafirlukast withdrawal, so they do
not seem predictable. A drop-off in adherence with
zafirlukast over the 12 weeks of the study is unlikely to be
an explanation for the gradual loss of benefit, as we
assessed this very carefully at each study visit and the
rebound deterioration observed only in subjects who
received zafirlukast, which would be very much against
poor adherence with active treatment.
We found no evidence of an anti-inflammatory effect for
zafirlukast, despite our assessment of sputum and periph-
eral blood eosinophils as well as AHR and eNO levels.
This would be against any worsening of inflammation
related to some "masking" effect to explain the loss of
clinical benefit over time. Following zafirlukast with-
drawal there was a significant increase in peripheral blood
neutrophils, especially in the β2-agonist group. Neu-
trophils express cysLT1 receptors and montelukast has
been shown to reduce sputum neutrophils in stable
COPD and there are also suggestions that neutrophil
function may be modulated by LRAs. [22-27]
Acute dosing with zafirlukast appeared to confer some
protection against methacholine-induced bronchocon-
striction in both asthmatic groups, but this was not signif-
icant compared to the effects of placebo and our study was
handicapped by the number of subjects, especially in the
zafirlukast arm, who did not undergo repeat challenge
testing at the end of active treatment or following with-
drawal because of clinical deterioration. However, despite
the small numbers available for analysis, PD20FEV1 did not
deteriorate in either group following withdrawal of
zafirlukast, suggesting that any acute protective effects
were small and that LTD4 hypersensitivity was not mani-
fest as increased AHR to methacholine.
One potential explanation for the clinical deteriorations
over time in those subjects receiving zafirlukast would be
up-regulation of LTD4 receptor expression in the airways,
including on smooth muscle cells, induced by chronic
receptor occupation by the LRA. Our data suggest that this
may occur irrespective of clinical benefit. The lesser "tach-
yphylaxis" and rebound in Group II suggests ICS may pro-
tect against this, but the confounding of better adherence
with disease-modifying ICS makes differences difficult to
interpret. If LTD4 receptor expression is indeed up-regu-
lated, then concomitant failure to reduce CysLT produc-
tion by airway eosinophils could result in excessive
receptor occupancy and activation on treatment with-
drawal. The existence of this sort of dynamic receptor reg-
ulation is well described with histamine (H2)-receptor
antagonists and explains the development of tolerance in
peptic ulcer disease and rebound acid hypersecretion on
drug withdrawal. H2-receptor antagonists demonstrate
"inverse agonist" activity which leads to increased H2-
receptor cell-surface expression. A recent short-term cell-
culture model has demonstrated that zafirlukast and
montelukast both function as reverse agonists causing
cells to increase surface expression of CysLT1 receptors.
This effect is likely to be much greater with longer-term
exposure to LRAs. The importance of these observations is
that they support the existence of dynamic cell-surface
CysLT1 receptor expression and lend biological plausibil-
ity to our explanation for the loss of asthma control over
time and rebound on LRA withdrawal. [28,29] Tachyphy-
laxis to β2-agonist therapy is another example of the
potential for dynamic receptor expression, although in
this context the effect is in the opposite direction with
down-regulation of cell surface receptors following long-
term exposure to agonist therapy. [30] Interestingly, ICS
are known to modulate the development of tachyphylaxis
to β2-agonists and although speculative, perhaps ICS also
affect CysLT1 receptor expression to explain the lesser evi-
dence of tolerance to zafirlukast in the ICS treated group
observed in our study, but this requires further investiga-
tion. [31]
The question still remains as to whether our findings indi-
cate a "class effect" or whether this is more likely with
zafirlukast. The in vitro demonstration of up-regulated
CysLT1 receptor expression with zafirlukast and montelu-
kast would suggest a class effect, but several long-term
clinical studies of montelukast have not suggested toler-
ance. [32] However, there are a number of reasons why
tolerance could be masked: 1) it was not specifically
looked for; 2) the population on average may not decline
sufficiently for the effect to become clinically obvious,
especially if improvements in a responsive sub-popula-
tion counter-balance deteriorations in the remainder. The
majority of absolute changes (deteriorations) in clinical
status and lung function seen in our subjects treated with
zafirlukast were quite small, albeit real, and would sup-
port this explanation. Additionally, drop-outs due to dete-
rioration would reinforce this false impression of well-
being in the "survivor population"; 3) ICS might modify
the effect or patients may increase the ICS dose to counter
any negative effects of tachyphylaxis that appear; 4)
higher doses of LRAs may overcome the effect; and finally,
5) importantly, age may be a factor in the response to
LRAs. Our asthmatic subjects who received zafirlukast
were generally older (median age 42 years), than in most
other studies of LRAs, which was just fortuitous.Page 9 of 11
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50 years demonstrated actual worsening of lung function
and an increased exacerbation rate on zafirlukast therapy.
[18] The same appeared true, but to a lesser extent, in sub-
jects over the age of 40. Masking of airway inflammation
was one of the explanations put forward, but our study
found no evidence for this. A further suggestion of poten-
tial tolerance comes from a Cochrane systematic review of
ICS versus LRA that demonstrated a substantially increased
risk of exacerbations with LRAs over treatment periods
longer than 12 weeks, although increased exacerbations
were already apparent even after only 4–8 weeks LRA ther-
apy. [33] This risk seemed highest with zafirlukast com-
pared to montelukast. Unfortunately, the reviewers did
not explore these observations and failed to consider tol-
erance or a potential age effect.
Our prospective data are very suggestive of a rebound
deterioration on cessation of drug – this would be highly
supportive of true tachyphylaxis and the increase in circu-
lating neutrophils is concerning. Our reading of the liter-
ature would suggest that these potential problems with
LRAs have not been looked for in a comprehensive fash-
ion despite several large studies and their current wide-
spread use. The possibility that age may influence the
effects of reverse agonist activity and dynamic receptor
expression is of particular concern and warrants further
specific assessment.
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